📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
1,000+ announcements match the current filters (relevance ≥ 5).
Chemplast Sanmar Restarts Karaikal EDC Plant; Machinery Damage Estimated at Rs 5 Cr
Chemplast Sanmar has recommenced operations at its Ethylene-Di-Chloride (EDC) manufacturing plant in Karaikal, Puducherry, on September 26, 2026, following provisional revocation of prohibition orders by the Inspector of Factories and Puducherry Pollution Control Committee (PPCC). Operations had been disrupted since July 18, 2026, following an incident. Plant and machinery damage is estimated at approximately Rs 5 crore, for which an insurance claim has been submitted. The PPCC will review operations before issuing a final revocation order, at which point total financial and production impacts will be quantified.
Confidence: HIGH
What changedChemplast Sanmar resumed operations at its Karaikal EDC plant after authorities granted provisional revocation of prohibition orders.
Why it mattersThe restart restores internal EDC feedstock supply for downstream operations after a shutdown exceeding two months, limiting further operational drag.
Estimated plant and machinery damage: Rs. 5 CroresDamage vs Net worth: ~0.16%Disruption period: July 18, 2026 to September 26, 2026
📅 Short termRemoves operational uncertainty around the Karaikal unit, though Q2 FY27 earnings will absorb production loss and unrecovered damages.
📈 Long termLimited; operational resumption restores standard production capacity without impacting structural long-term fundamentals.
⚠ Risk flags
- Final revocation from PPCC is pending post-restart review
- Full production and financial impact has not yet been quantified
Key Highlights
Recommenced operations at Karaikal EDC plant on September 26, 2026, after disruption since July 18, 2026
Received provisional revocation of prohibition orders from Inspector of Factories and PPCC
Estimated plant and machinery damage is Rs 5 crore (0.16% of Net Worth)
Root Cause Analysis and HAZOP study completed to implement corrective measures
Overall production and financial loss impact to be quantified upon final revocation
👀 What to Watch
Track the receipt of the final revocation order from PPCC and the quantified impact of the ~2-month shutdown on Q2 FY27 operational earnings.
Khadim Allots 10.23 Lakh Convertible Warrants at ₹110 Each to Raise ₹11.25 Cr
Khadim India Limited has approved the allotment of 10,22,727 fully convertible equity share warrants on a preferential basis at an issue price of ₹110 per warrant. The total issue size stands at ₹11.25 crore, representing about 5.2% of the company's current market capitalization of ₹216 crore. The company has collected 25% of the subscription price upfront, with the remaining 75% payable upon exercise within 18 months. Promoter Siddhartha Roy Burman was allotted 2,27,273 warrants, which will increase his equity holding from 8.89% to 9.59% upon full conversion.
Confidence: HIGH
What changedKhadim allotted 10,22,727 convertible warrants to promoters and public investors following board and shareholder approvals.
Why it mattersThe preferential issue injects an initial ~₹2.81 crore upfront and up to ₹11.25 crore in total equity capital to support cash flow, while causing modest dilution across the share base.
Warrants allotted: 10,22,727Issue price per warrant: ₹ 110/-Total fundraise value: ₹ 11,24,99,970/-Fundraise vs Market Cap: ~5.2%Warrant tenure: 18 (Eighteen) months
📅 Short termNeutral trading impact as the issue price of ₹110 is slightly below the current market price of ₹118.1, and the initial cash influx is modest (~₹2.81 crore).
📈 Long termProvides incremental equity infusion (~₹11.25 crore total), aiding the debt-heavy balance sheet (debt of ₹249 crore) in a minor capacity.
⚠ Risk flags
- Equity dilution of ~5% upon full conversion of warrants
- Risk of warrant forfeiture if market price drops below ₹110 over the 18-month exercise window
Key Highlights
Allotment of 10,22,727 convertible warrants approved at ₹110 per share
Total issue value aggregates to ₹11,24,99,970 (~₹11.25 crore)
25% upfront subscription amount received, with 75% payable on exercise within 18 months
Promoter Siddhartha Roy Burman allotted 2,27,273 warrants, raising his stake to 9.59% post-conversion
👀 What to Watch
Monitor warrant exercise timelines over the 18-month window and track the deployment of capital toward store expansion or working capital.
R Systems Declares ₹8/Share Interim Dividend (800%), Appoints Gurprit Singh as CS
R Systems International declared a Second Interim Dividend for 2026 of ₹8 per equity share of face value Re. 1 (800%). The Record Date has been fixed as October 01, 2026, with the payout scheduled on or before October 24, 2026. Relative to the current share price of ₹235.6, this single interim dividend represents an immediate yield of approximately 3.4%. Concurrently, the company appointed Mr. Gurprit Singh as Company Secretary and Compliance Officer effective September 25, 2026.
Confidence: HIGH
What changedR Systems approved a ₹8/share interim dividend and appointed Gurprit Singh as the new CS & Compliance Officer.
Why it mattersDemonstrates healthy shareholder capital returns (3.4% single-dividend yield on a ₹235.6 share price) supported by strong annualized profitability (TTM PAT of ₹193 Cr).
Interim Dividend per share: Rs. 8/-Dividend percentage: 800%Record Date: October 01, 2026Dividend yield on current price: ~3.4%
📅 Short termStock may witness trading interest leading up to the October 01, 2026 record date due to the sizable cash payout.
📈 Long termLimited structural change; underscores ongoing cash generation and capital return discipline under Blackstone backing.
Key Highlights
Second Interim Dividend declared at ₹8 per equity share of face value Re. 1 (800%)
Record date for dividend entitlement fixed as Thursday, October 01, 2026
Dividend payment date scheduled on or before October 24, 2026
Appointment of Mr. Gurprit Singh as Company Secretary & Compliance Officer w.e.f. September 25, 2026
Dividend declared at 0.0001% on Re. 1 face value OCRPS
👀 What to Watch
Track the ex-dividend date preceding the October 01, 2026 record date for dividend eligibility, and monitor subsequent cash outflows against the company's net profit and balance sheet cash.
MPEL Allots 1.55 Cr Rights Equity Shares at ₹16/Share to Raise ~₹24.88 Cr
Manas Polymers and Energies Limited (MPEL) has approved the allotment of 1,55,52,000 equity shares on a rights basis at an issue price of ₹16 per share (face value ₹10 plus a premium of ₹6). The allotment triples the company's equity base, raising paid-up share capital from ₹7.78 crore to ₹23.33 crore. Total proceeds raised through this rights issue stand at approximately ₹24.88 crore.
Confidence: HIGH
What changedThe Rights Issue Committee approved the final allotment of 1.55 crore shares, expanding the total share count from 77.76 lakh to 2.33 crore shares.
Why it mattersThe company secures approximately ₹24.88 crore in equity capital, though existing non-participating shareholders face significant dilution with share count increasing by 200%.
Shares Allotted: 1,55,52,000Issue Price per Share: INR 16Pre-issue Paid-up Capital: INR 7,77,60,000Post-issue Paid-up Capital: INR 23,32,80,000
📅 Short termNewly allotted shares will be credited to demat accounts and listed on the NSE, which may lead to short-term price adjustments reflecting the expanded float.
📈 Long termLong-term impact hinges on how effectively the ₹24.88 crore is deployed toward working capital or capex to offset the 3x equity dilution.
⚠ Risk flags
- Equity dilution (share count tripled from 77.76 lakh to 2.33 crore shares)
Key Highlights
Allotted 1,55,52,000 equity shares of face value ₹10 each on a rights basis
Issue price fixed at ₹16 per equity share (including a ₹6 premium)
Paid-up share capital increased from ₹7,77,60,000 (77.76 lakh shares) to ₹23,32,80,000 (2.33 crore shares)
Total capital raised stands at approximately ₹24.88 crore
👀 What to Watch
Track the credit and listing date of the newly allotted rights shares, and monitor management's utilization of proceeds as outlined in the Letter of Offer.
MPEL Allots 1.55 Cr Rights Equity Shares at ₹16/Share to Raise ~₹24.88 Cr
Manas Polymers and Energies Limited (MPEL) has approved the allotment of 1,55,52,000 equity shares on a rights basis at an issue price of ₹16 per share (face value ₹10 plus a premium of ₹6). The allotment triples the company's equity base, raising paid-up share capital from ₹7.78 crore to ₹23.33 crore. Total proceeds raised through this rights issue stand at approximately ₹24.88 crore.
Confidence: HIGH
What changedThe Rights Issue Committee approved the final allotment of 1.55 crore shares, expanding the total share count from 77.76 lakh to 2.33 crore shares.
Why it mattersThe company secures approximately ₹24.88 crore in equity capital, though existing non-participating shareholders face significant dilution with share count increasing by 200%.
Shares Allotted: 1,55,52,000Issue Price per Share: INR 16Pre-issue Paid-up Capital: INR 7,77,60,000Post-issue Paid-up Capital: INR 23,32,80,000
📅 Short termNewly allotted shares will be credited to demat accounts and listed on the NSE, which may lead to short-term price adjustments reflecting the expanded float.
📈 Long termLong-term impact hinges on how effectively the ₹24.88 crore is deployed toward working capital or capex to offset the 3x equity dilution.
⚠ Risk flags
- Equity dilution (share count tripled from 77.76 lakh to 2.33 crore shares)
Key Highlights
Allotted 1,55,52,000 equity shares of face value ₹10 each on a rights basis
Issue price fixed at ₹16 per equity share (including a ₹6 premium)
Paid-up share capital increased from ₹7,77,60,000 (77.76 lakh shares) to ₹23,32,80,000 (2.33 crore shares)
Total capital raised stands at approximately ₹24.88 crore
👀 What to Watch
Track the credit and listing date of the newly allotted rights shares, and monitor management's utilization of proceeds as outlined in the Letter of Offer.
Lamosaic India Approves Up to ₹49.87 Cr Rights Issue and Board Reconstitution
Lamosaic India Limited's Board has approved raising funds up to ₹4,987.06 Lakhs (~₹49.87 crore) via a Rights Issue of fully paid-up equity shares. Against the company's net worth of ₹79 crore, the fundraise represents ~63.1% of net worth, making it a highly material capital expansion. Alongside the fundraise, the Board approved the re-designation of Promoter Vinod Juthalal Visaria from Managing Director to Whole-Time Director for 3 years, and accepted resignations of directors Jay Manilal Chheda and Jitesh Khushalchand Mamaniya (who remains CFO).
Confidence: HIGH
What changedThe company authorized a rights issue of up to ₹49.87 crore and reshuffled executive roles and board committee compositions.
Why it mattersA fundraise of this size relative to net worth (~63%) will substantially impact share capital and dilute non-participating shareholders, but could significantly strengthen liquidity.
Rights Issue Size: Up to Rs. 4,987.06 LakhsIssue Size vs Net Worth: ~63.1%Issue Size vs TTM Revenue: ~20.3%Whole-Time Director Tenure: 3 years
📅 Short termMarket attention will focus on the determination of the rights issue price and discount to current market price, as well as the entitlement ratio.
📈 Long termIf deployed effectively, the proceeds could support working capital or manufacturing optimization, but overall value creation depends on returning the business to steady profitability.
⚠ Risk flags
- Equity dilution risk for shareholders who do not participate in the Rights Issue
- Pricing, ratio, and precise end-use of proceeds are yet to be finalized by the Board
Key Highlights
Board approved raising up to ₹4,987.06 Lakhs (~₹49.87 crore) through a Rights Issue
Fundraise represents ~63.1% of the company's net worth (₹79 crore) and ~20.3% of TTM revenue (₹246 crore)
Vinod Juthalal Visaria re-designated from Managing Director to Whole-Time Director for a period of 3 years
Jay Manilal Chheda resigned as Non-Executive Director effective 25 September 2026
Jitesh Khushalchand Mamaniya resigned as Director effective 25 September 2026 but continues as CFO
👀 What to Watch
Track upcoming filings for the Rights Issue entitlement ratio, issue price, record date, and specific end-use of proceeds.
Lamosaic India Approves Up to Rs 49.87 Cr Rights Issue; Announces Board Restructuring
Lamosaic India Limited's Board has approved raising up to Rs 4,987.06 Lakhs (~Rs 49.87 Cr) via a rights issue of fully paid-up equity shares. Relative to the company's net worth of Rs 79 Cr, this proposed capital raise represents ~63% of net worth, making it a sizable corporate action. Additionally, the Board approved the re-designation of Promoter Vinod Juthalal Visaria from Managing Director to Whole-Time Director for 3 years, while Jay Manilal Chheda resigned as Non-Executive Director. Jitesh Khushalchand Mamaniya stepped down from the directorship to focus on his executive role as CFO, and Board committees were reconstituted.
Confidence: HIGH
What changedThe company approved a rights issue of up to Rs 49.87 Cr and revamped its Board leadership, moving the MD to a Whole-Time Director role and accepting two director resignations.
Why it mattersA fundraise of ~Rs 49.87 Cr significantly alters the capital base for a company with Rs 79 Cr net worth, potentially funding expansion or working capital, though it introduces equity dilution risk for non-participating shareholders.
Max rights issue size: Rs. 4,987.06 LakhsRights issue vs Net worth: ~63.1%Rights issue vs TTM revenue: ~20.3%Whole-Time Director appointment tenure: 3 yearsEffective date of changes: 25 September, 2026
📅 Short termInvestors will focus on the determination of the rights issue price and discount to market price once terms and record dates are established.
📈 Long termDepending on fund deployment, the capital infusion could strengthen balance sheet resilience and support manufacturing capacity, though returns will depend on improving low TTM ROCE (5.0%).
⚠ Risk flags
- Dilution risk if existing shareholders do not subscribe to the rights issue
- Lack of detailed capital expenditure/utilization plan in the current disclosure
- Executive-level shuffle at the Board level
Key Highlights
Approved rights issue to raise up to Rs 4,987.06 Lakhs (~Rs 49.87 Cr)
Proposed fundraise equals ~63% of existing net worth of Rs 79 Cr and ~20% of TTM revenue of Rs 246 Cr
Vinod Juthalal Visaria re-designated from Managing Director to Whole-Time Director for a term of 3 years
Resignation of Jay Manilal Chheda and cessation of directorship of CFO Jitesh Mamaniya effective 25 September 2026
Reconstitution of Audit and Stakeholders Relationship Committees completed
👀 What to Watch
Track the upcoming disclosure of the rights entitlement ratio, issue price, and record date, as well as the stated utilization plan for the Rs 49.87 Cr proceeds.
Lamosaic India Approves Up to Rs 49.87 Cr Rights Issue; Announces Board Restructuring
Lamosaic India Limited's Board has approved raising up to Rs 4,987.06 Lakhs (~Rs 49.87 Cr) via a rights issue of fully paid-up equity shares. Relative to the company's net worth of Rs 79 Cr, this proposed capital raise represents ~63% of net worth, making it a sizable corporate action. Additionally, the Board approved the re-designation of Promoter Vinod Juthalal Visaria from Managing Director to Whole-Time Director for 3 years, while Jay Manilal Chheda resigned as Non-Executive Director. Jitesh Khushalchand Mamaniya stepped down from the directorship to focus on his executive role as CFO, and Board committees were reconstituted.
Confidence: HIGH
What changedThe company approved a rights issue of up to Rs 49.87 Cr and revamped its Board leadership, moving the MD to a Whole-Time Director role and accepting two director resignations.
Why it mattersA fundraise of ~Rs 49.87 Cr significantly alters the capital base for a company with Rs 79 Cr net worth, potentially funding expansion or working capital, though it introduces equity dilution risk for non-participating shareholders.
Max rights issue size: Rs. 4,987.06 LakhsRights issue vs Net worth: ~63.1%Rights issue vs TTM revenue: ~20.3%Whole-Time Director appointment tenure: 3 yearsEffective date of changes: 25 September, 2026
📅 Short termInvestors will focus on the determination of the rights issue price and discount to market price once terms and record dates are established.
📈 Long termDepending on fund deployment, the capital infusion could strengthen balance sheet resilience and support manufacturing capacity, though returns will depend on improving low TTM ROCE (5.0%).
⚠ Risk flags
- Dilution risk if existing shareholders do not subscribe to the rights issue
- Lack of detailed capital expenditure/utilization plan in the current disclosure
- Executive-level shuffle at the Board level
Key Highlights
Approved rights issue to raise up to Rs 4,987.06 Lakhs (~Rs 49.87 Cr)
Proposed fundraise equals ~63% of existing net worth of Rs 79 Cr and ~20% of TTM revenue of Rs 246 Cr
Vinod Juthalal Visaria re-designated from Managing Director to Whole-Time Director for a term of 3 years
Resignation of Jay Manilal Chheda and cessation of directorship of CFO Jitesh Mamaniya effective 25 September 2026
Reconstitution of Audit and Stakeholders Relationship Committees completed
👀 What to Watch
Track the upcoming disclosure of the rights entitlement ratio, issue price, and record date, as well as the stated utilization plan for the Rs 49.87 Cr proceeds.
R Systems Declares Second Interim Dividend of ₹8 Per Share (800%), Sets Record Date as Oct 1, 2026
R Systems International has declared a second interim dividend of ₹8 per equity share of face value ₹1 each (800%) for the year 2026. The record date to determine shareholder eligibility is fixed as October 1, 2026, with the payout scheduled on or before October 24, 2026. Relative to the current share price of ₹235.6, this interim dividend represents a yield of approximately 3.4%. Additionally, the company appointed Mr. Gurprit Singh as Company Secretary and Compliance Officer effective September 25, 2026.
Confidence: HIGH
What changedR Systems approved an ₹8 per share second interim dividend and appointed a new Company Secretary & Compliance Officer.
Why it mattersThe dividend delivers an immediate cash return of ~3.4% on the current share price (₹235.6), continuing cash distributions supported by trailing 12-month net profit of ₹193 Cr.
Interim Dividend per share: Rs. 8Dividend percentage: 800%Record Date: October 01, 2026Payment deadline: October 24, 2026Dividend Yield on CMP: ~3.4%
📅 Short termThe stock will react to the attractive interim payout ahead of the October 1, 2026 record date, after which it will adjust for the ₹8 payout.
📈 Long termLimited; reflects routine capital return policy backed by healthy cash flows and low leverage (D/E 0.56).
Key Highlights
Declared Second Interim Dividend of ₹8 per equity share of face value ₹1 (800%)
Record date set for Thursday, October 1, 2026
Payment to be completed on or before October 24, 2026
Appointed Gurprit Singh as Company Secretary and Compliance Officer w.e.f. September 25, 2026
Declared a dividend of 0.0001% per Re. 1/- face value on Optionally Convertible Redeemable Preference Shares
👀 What to Watch
Track the ex-dividend date around September 30 or October 1, 2026, for dividend entitlement, followed by payment disbursement by October 24, 2026.
QMS and HCAH Sign Definitive Deal to Merge PSP Businesses into Saarathi Healthcare
QMS Medical Allied Services and Health Care At Home India (HCAH) have signed definitive documents to merge their pharma services businesses into Saarathi Healthcare, a 100% subsidiary of QMS. The combined platform will operate over 160 Patient Support Programs (PSPs) reaching more than 1.2 million patients with a workforce of 2,000+ professionals across 35+ cities. The strategic combination positions QMS to capitalize on India's PSP market, which is projected to reach approximately US$1 billion by 2030, growing at 15-20% CAGR.
Confidence: HIGH
What changedQMS and HCAH have entered a definitive agreement to consolidate their pharma services and PSP operations under QMS's subsidiary, Saarathi Healthcare.
Why it mattersThe deal significantly enhances QMS's high-margin services segment (which commands 20-22% margins compared to 10-12% in products) by creating India's largest patient support program platform.
Patient Support Programs: 160+Patients impacted: 1.2 million+Team strength: 2,000+ professionalsGeographical footprint: 35+ citiesTarget India market by 2030: c.US$1 billion
📅 Short termPositive sentiment is expected following definitive documentation with an established institutional player (backed by Burmans and Quadria Capital), though transaction valuation details remain undisclosed.
📈 Long termPositions Saarathi as a dominant national player in PSPs, directly feeding QMS's strategy to scale higher-margin service revenues and improve overall ROCE.
⚠ Risk flags
- Financial terms, valuation, and post-merger shareholding structure of Saarathi were not disclosed in the press release
- Integration risks spanning 2,000+ personnel across 35+ cities
Key Highlights
Definitive agreement signed to merge PSP businesses of HCAH and QMS into Saarathi Healthcare, a 100% subsidiary of QMS
Combined platform will operate 160+ Patient Support Programs impacting over 1.2 million+ patients
Deployment of 2,000+ professionals across 35+ cities serving top Indian and MNC pharma clients
Addresses an Indian PSP market expanding at 15-20% CAGR to reach ~US$1 billion by 2030 (global market at ~US$70 billion)
👀 What to Watch
Track subsequent regulatory disclosures for final share-swap or equity structure details in Saarathi Healthcare, along with revenue contribution in upcoming quarterly reports.
Acuité Assigns 'ACUITE BBB/Stable' Rating to ANB Metal Cast's ₹59.00 Cr Bank Facilities
Acuité Ratings & Research has assigned a long-term credit rating of 'ACUITE BBB' with a 'Stable' outlook to ANB Metal Cast Limited's ₹59.00 crore bank loan facilities. The rationale highlights the company's revenue growth to ₹225.19 crore in FY26 from ₹162.57 crore in FY25 (a 2-year CAGR of 41.70%) and net worth expansion to ₹98.34 crore. The rating is supported by a conservative gearing ratio of 0.50x and interest coverage of 11.12x, though constrained by working capital intensity with GCA days at 263 days.
Confidence: HIGH
What changedANB Metal Cast has secured a formal investment-grade credit rating of 'ACUITE BBB/Stable' from Acuité for its ₹59.00 crore bank facilities.
Why it mattersAn investment-grade rating validates the company's financial risk profile post-IPO and aids access to competitive bank credit for ongoing and future expansions.
Rated Bank Facilities: ₹59.00 CrFY26 Operating Income: ₹225.19 CrFY26 Operating Margin: 14.41%FY26 Gearing Ratio: 0.50xProposed Capex: ~₹15 Cr
📅 Short termNeutral to slightly positive sentiment driven by validation of an investment-grade rating from a registered rating agency.
📈 Long termComfortable leverage (0.50x D/E) provides headroom for funding the ongoing extrusion capacity doubling to 18,000 MTPA, but working capital intensity remains a structural drag.
⚠ Risk flags
- High working capital intensity with GCA at 263 days and debtor days at 110 days in FY26
- Exposure to volatility in aluminium raw material prices and cyclicality in end-user industries
- Debt portion of ~₹5 Cr for the upcoming ₹15 Cr capex is yet to be tied up
Key Highlights
Assigned new credit rating of 'ACUITE BBB' with 'Stable' outlook for ₹59.00 Cr bank loan facilities
Operating income rose to ₹225.19 Cr in FY26 compared to ₹162.57 Cr in FY25, reflecting a 41.70% 2-year CAGR
Operating margin expanded to 14.41% in FY26 (up from 10.71% in FY25), with PAT margin at 9.53%
Gearing stood low at 0.50x in FY26 with interest coverage ratio at 11.12x, against total debt of ₹48.74 Cr
Proposed ₹15 Cr capex to expand extrusion press capacity from 9,800 MTPA to 18,000 MTPA by January 2027
👀 What to Watch
Track the execution and debt tie-up of the ₹15 crore extrusion capacity expansion targeted for January 2027, alongside working capital efficiency as GCA days stretch to 263 days.
V-Marc India Shareholders Approve Main Board Migration and Borrowing Limit Enhancements at 13th AGM
V-Marc India announced the voting results and Scrutinizer's Report for its 13th AGM held on September 25, 2026. Shareholders approved all 11 resolutions with requisite majority, including the migration from the NSE SME platform to the Main Board of NSE and direct listing on BSE. Other key approvals included enhancing borrowing limits under Section 180(1)(c) and creation of charges under Section 180(1)(a), along with related party transactions. Resolution 9 for Main Board migration received 100% approval on the 9,87,80,676 votes cast.
Confidence: HIGH
What changedShareholders formally approved all AGM agenda items, most notably enabling the company's migration from SME to the NSE Main Board and BSE direct listing.
Why it mattersMigration to the Main Board broadens institutional investor access, improves liquidity, and borrowing limit expansions support the company's long-term capacity ramp-up plans.
Votes in favor of Main Board migration: 9,87,80,676Total shareholders on cut-off date: 3,862AGM date: 25th Sept 2026
📅 Short termNeutral to mildly positive as formal shareholder consent allows management to file for regulatory Main Board migration clearances.
📈 Long termMain Board listing and higher borrowing capacities support potential scaling of manufacturing facilities and enhanced market visibility.
⚠ Risk flags
- Execution of Main Board migration is subject to final stock exchange approvals and SEBI listing compliance
- Related-party transactions approved during the AGM
Key Highlights
Resolution 9 approving migration to NSE Main Board and direct listing on BSE passed with 100% votes in favor (9,87,80,676 votes)
Enhancement of borrowing and asset-disposal limits under Sections 180(1)(c) and 180(1)(a) approved with 99.99% majority
Approval of related-party transactions (Resolutions 10 & 11) approved with >99.6% shareholder support
Total shareholders as of the cut-off date stood at 3,862
👀 What to Watch
Track subsequent exchange filings for the formal in-principle and final listing approvals from NSE and BSE regarding the Main Board migration timeline.
QMS Medical Approves Demerger of Services Arm into Saarathi Healthcare (1:1 Share Swap)
QMS Medical Allied Services has approved a Composite Scheme of Arrangement to demerge its Healthcare Services Business (revenue of Rs 37.17 Cr, ~24.41% of FY26 turnover) into Saarathi Healthcare. In addition, the healthcare services division of Health Care at Home India (HCAH) is also being merged into Saarathi, creating a combined healthcare services entity to be listed separately. Under the scheme, QMS shareholders will receive 1 share of Saarathi Healthcare (face value Rs 10) for every 1 share held in QMS. Concurrently, QMS entered into an MoU to acquire 100% of BeamOptics Scientific Pvt Ltd (FY26 revenue Rs 1.14 Cr) by November 30, 2027.
Confidence: HIGH
What changedQMS approved demerging its Healthcare Services Business and combining it with HCAH's service business under Saarathi Healthcare, which will be separately listed.
Why it mattersSeparates the high-margin healthcare services division into a dedicated listed entity, unlocking direct shareholder value via a 1:1 share distribution while maintaining QMS's core medical products business.
Demerged division FY26 turnover: Rs. 37.17 CroresDemerged share of FY26 turnover: 24.41%Share swap ratio (QMS to Saarathi): 1:1Saarathi post-arrangement total shares: 3,25,00,066BeamOptics FY26 turnover: Rs. 113.81 Lakhs
📅 Short termMarket may view the planned separate listing and 1:1 mirror share distribution positively, though stock exchange and NCLT approval timelines are lengthy.
📈 Long termConsolidates Saarathi and HCAH service businesses to create a scaled patient-support service provider, giving shareholders direct equity in two distinct corporate vehicles.
⚠ Risk flags
- Subject to approvals from NCLT, NSE, shareholders, and creditors
- Indicative completion timeline spans well into 2027
- Valuation and cash/equity consideration for BeamOptics acquisition yet to be finalized
Key Highlights
Demerged division contributed Rs 37.17 Cr, or 24.41% of QMS turnover in FY26
Share swap ratio set at 1 equity share of Saarathi Healthcare for every 1 share held in QMS
Post-arrangement Saarathi shareholding will be 40.5% Promoter and 59.5% Public (3.25 Cr total shares)
Proposed 100% acquisition of BeamOptics Scientific (FY26 revenue Rs 113.81 Lakhs) targeted by November 30, 2027
👀 What to Watch
Track the regulatory approvals process, including NCLT clearance, shareholder voting, and creditor consents for the scheme of arrangement.
RBM Infracon CFO Narendra Kumar Sharma Resigns; Vipin Goyal Appointed Interim CFO
RBM Infracon announced that Mr. Narendra Kumar Sharma has resigned from the position of Chief Financial Officer effective September 25, 2026, citing pre-occupation with other professional commitments. Concurrently, the Board has appointed Mr. Vipin Goyal, a finance professional with over 18 years of experience, as Interim CFO and Key Managerial Personnel. The transition occurs as the company manages an order book of Rs 4,531.26 Cr against TTM revenue of Rs 748 Cr. No other material reasons were stated for the outgoing CFO's departure.
Confidence: HIGH
What changedMr. Narendra Kumar Sharma stepped down as CFO, and Mr. Vipin Goyal took over as Interim CFO on September 25, 2026.
Why it mattersA transition in the CFO seat is critical for maintaining internal financial controls, working capital management, and debt oversight (current debt stands at Rs 142 Cr).
Effective date of change: September 25, 2026Incoming Interim CFO experience: over 18 yearsTTM Revenue (context): Rs 748 CrOrder book (context): INR 4,531.26 Cr
📅 Short termRoutine administrative transition; no immediate operational disruption is anticipated over the coming days.
📈 Long termLimited, provided the company smoothly finalizes a permanent CFO appointment to oversee working capital for its expanded order book.
⚠ Risk flags
- Key managerial turnover at the CFO position
- Interim nature of the CFO appointment until a permanent successor is named
Key Highlights
CFO Narendra Kumar Sharma resigned with effect from September 25, 2026
Mr. Vipin Goyal appointed as Interim Chief Financial Officer and KMP effective September 25, 2026
New Interim CFO brings over 18 years of finance experience across manufacturing, automotive, retail, and power sectors
Board meeting commenced at 6:00 PM and concluded at 6:30 PM on September 25, 2026
👀 What to Watch
Monitor the company's subsequent filings for the appointment of a permanent CFO and observe whether financial reporting timelines or capital allocation across ongoing projects remain seamless.
QMS Medical Approves Demerger of Services Arm into Saarathi Healthcare (1:1 Share Swap)
QMS Medical Allied Services has approved a Composite Scheme of Arrangement to demerge its Healthcare Services Business (revenue of Rs 37.17 Cr, ~24.41% of FY26 turnover) into Saarathi Healthcare. In addition, the healthcare services division of Health Care at Home India (HCAH) is also being merged into Saarathi, creating a combined healthcare services entity to be listed separately. Under the scheme, QMS shareholders will receive 1 share of Saarathi Healthcare (face value Rs 10) for every 1 share held in QMS. Concurrently, QMS entered into an MoU to acquire 100% of BeamOptics Scientific Pvt Ltd (FY26 revenue Rs 1.14 Cr) by November 30, 2027.
Confidence: HIGH
What changedQMS approved demerging its Healthcare Services Business and combining it with HCAH's service business under Saarathi Healthcare, which will be separately listed.
Why it mattersSeparates the high-margin healthcare services division into a dedicated listed entity, unlocking direct shareholder value via a 1:1 share distribution while maintaining QMS's core medical products business.
Demerged division FY26 turnover: Rs. 37.17 CroresDemerged share of FY26 turnover: 24.41%Share swap ratio (QMS to Saarathi): 1:1Saarathi post-arrangement total shares: 3,25,00,066BeamOptics FY26 turnover: Rs. 113.81 Lakhs
📅 Short termMarket may view the planned separate listing and 1:1 mirror share distribution positively, though stock exchange and NCLT approval timelines are lengthy.
📈 Long termConsolidates Saarathi and HCAH service businesses to create a scaled patient-support service provider, giving shareholders direct equity in two distinct corporate vehicles.
⚠ Risk flags
- Subject to approvals from NCLT, NSE, shareholders, and creditors
- Indicative completion timeline spans well into 2027
- Valuation and cash/equity consideration for BeamOptics acquisition yet to be finalized
Key Highlights
Demerged division contributed Rs 37.17 Cr, or 24.41% of QMS turnover in FY26
Share swap ratio set at 1 equity share of Saarathi Healthcare for every 1 share held in QMS
Post-arrangement Saarathi shareholding will be 40.5% Promoter and 59.5% Public (3.25 Cr total shares)
Proposed 100% acquisition of BeamOptics Scientific (FY26 revenue Rs 113.81 Lakhs) targeted by November 30, 2027
👀 What to Watch
Track the regulatory approvals process, including NCLT clearance, shareholder voting, and creditor consents for the scheme of arrangement.
NCLT Approves First Motion for Demerger of Paper Business into Magnum Paperz
Magnum Ventures received the NCLT Allahabad Bench order approving the First Motion application for its Scheme of Arrangement. Under the proposed scheme, the company will demerge its core Paper Business into Magnum Paperz Limited, leaving the hospitality vertical (Country Inn & Suites by Radisson) in the listed entity. The tribunal has directed convening meetings for equity shareholders, secured debenture holders, and creditors, while dispensing with meetings for preference shareholders. This initiates the formal restructuring process to separate its capital-intensive paper operations (TTM revenue Rs 473 Cr) from its hotel division.
Confidence: HIGH
What changedNCLT Allahabad Bench has allowed the First Motion application, advancing the corporate restructuring to spin off the paper division into a separate company.
Why it mattersThe demerger creates two distinct entities for paper manufacturing and hotel operations, allowing independent capital allocation, fund-raising, and operational focus.
Order Pronouncement Date: 22.09.2026Resulting Company Incorporation Date: 22nd September, 2025Chairperson Report Submission Timeline: within 7 (seven) working days of the conclusion of the meetingsRegulator Notice Period: within a period of 30 days
📅 Short termShareholders will receive formal notices setting out the voting dates and detailed scheme documents.
📈 Long termIf approved by stakeholders and sanctioned in the second motion, separating hospitality from commodity paper manufacturing could unlock value and streamline debt obligations.
⚠ Risk flags
- Scheme is subject to approval by shareholders, secured and unsecured creditors
- Final approval is contingent on Second Motion sanction by the NCLT and regulatory non-objections
Key Highlights
NCLT Allahabad Bench pronounced the First Motion order on 22nd September 2026 (uploaded 25th September 2026)
Paper Business to be demerged into Magnum Paperz Limited, which was incorporated on 22nd September, 2025
Shareholder and creditor meetings directed to be convened via video conferencing with e-voting facilities
Requirement to convene meeting of Preference Shareholders of the Demerged Company was dispensed with
👀 What to Watch
Track the notices and dates for the upcoming shareholder and creditor meetings, as well as the share entitlement ratio once formally notified.
QMS Medical Approves Demerger of Services Arm into Saarathi Healthcare (1:1 Share Swap)
QMS Medical Allied Services has approved a Composite Scheme of Arrangement to demerge its Healthcare Services Business (revenue of Rs 37.17 Cr, ~24.41% of FY26 turnover) into Saarathi Healthcare. In addition, the healthcare services division of Health Care at Home India (HCAH) is also being merged into Saarathi, creating a combined healthcare services entity to be listed separately. Under the scheme, QMS shareholders will receive 1 share of Saarathi Healthcare (face value Rs 10) for every 1 share held in QMS. Concurrently, QMS entered into an MoU to acquire 100% of BeamOptics Scientific Pvt Ltd (FY26 revenue Rs 1.14 Cr) by November 30, 2027.
Confidence: HIGH
What changedQMS approved demerging its Healthcare Services Business and combining it with HCAH's service business under Saarathi Healthcare, which will be separately listed.
Why it mattersSeparates the high-margin healthcare services division into a dedicated listed entity, unlocking direct shareholder value via a 1:1 share distribution while maintaining QMS's core medical products business.
Demerged division FY26 turnover: Rs. 37.17 CroresDemerged share of FY26 turnover: 24.41%Share swap ratio (QMS to Saarathi): 1:1Saarathi post-arrangement total shares: 3,25,00,066BeamOptics FY26 turnover: Rs. 113.81 Lakhs
📅 Short termMarket may view the planned separate listing and 1:1 mirror share distribution positively, though stock exchange and NCLT approval timelines are lengthy.
📈 Long termConsolidates Saarathi and HCAH service businesses to create a scaled patient-support service provider, giving shareholders direct equity in two distinct corporate vehicles.
⚠ Risk flags
- Subject to approvals from NCLT, NSE, shareholders, and creditors
- Indicative completion timeline spans well into 2027
- Valuation and cash/equity consideration for BeamOptics acquisition yet to be finalized
Key Highlights
Demerged division contributed Rs 37.17 Cr, or 24.41% of QMS turnover in FY26
Share swap ratio set at 1 equity share of Saarathi Healthcare for every 1 share held in QMS
Post-arrangement Saarathi shareholding will be 40.5% Promoter and 59.5% Public (3.25 Cr total shares)
Proposed 100% acquisition of BeamOptics Scientific (FY26 revenue Rs 113.81 Lakhs) targeted by November 30, 2027
👀 What to Watch
Track the regulatory approvals process, including NCLT clearance, shareholder voting, and creditor consents for the scheme of arrangement.
QMS Medical Approves Demerger of Services Arm into Saarathi Healthcare (1:1 Share Swap)
QMS Medical Allied Services has approved a Composite Scheme of Arrangement to demerge its Healthcare Services Business (revenue of Rs 37.17 Cr, ~24.41% of FY26 turnover) into Saarathi Healthcare. In addition, the healthcare services division of Health Care at Home India (HCAH) is also being merged into Saarathi, creating a combined healthcare services entity to be listed separately. Under the scheme, QMS shareholders will receive 1 share of Saarathi Healthcare (face value Rs 10) for every 1 share held in QMS. Concurrently, QMS entered into an MoU to acquire 100% of BeamOptics Scientific Pvt Ltd (FY26 revenue Rs 1.14 Cr) by November 30, 2027.
Confidence: HIGH
What changedQMS approved demerging its Healthcare Services Business and combining it with HCAH's service business under Saarathi Healthcare, which will be separately listed.
Why it mattersSeparates the high-margin healthcare services division into a dedicated listed entity, unlocking direct shareholder value via a 1:1 share distribution while maintaining QMS's core medical products business.
Demerged division FY26 turnover: Rs. 37.17 CroresDemerged share of FY26 turnover: 24.41%Share swap ratio (QMS to Saarathi): 1:1Saarathi post-arrangement total shares: 3,25,00,066BeamOptics FY26 turnover: Rs. 113.81 Lakhs
📅 Short termMarket may view the planned separate listing and 1:1 mirror share distribution positively, though stock exchange and NCLT approval timelines are lengthy.
📈 Long termConsolidates Saarathi and HCAH service businesses to create a scaled patient-support service provider, giving shareholders direct equity in two distinct corporate vehicles.
⚠ Risk flags
- Subject to approvals from NCLT, NSE, shareholders, and creditors
- Indicative completion timeline spans well into 2027
- Valuation and cash/equity consideration for BeamOptics acquisition yet to be finalized
Key Highlights
Demerged division contributed Rs 37.17 Cr, or 24.41% of QMS turnover in FY26
Share swap ratio set at 1 equity share of Saarathi Healthcare for every 1 share held in QMS
Post-arrangement Saarathi shareholding will be 40.5% Promoter and 59.5% Public (3.25 Cr total shares)
Proposed 100% acquisition of BeamOptics Scientific (FY26 revenue Rs 113.81 Lakhs) targeted by November 30, 2027
👀 What to Watch
Track the regulatory approvals process, including NCLT clearance, shareholder voting, and creditor consents for the scheme of arrangement.
QMS Medical approves demerger of services division & 100% buyout of BeamOptics
QMS Medical Allied Services has approved a Composite Scheme of Arrangement to demerge its Healthcare Services Business (revenue of Rs 37.17 Cr, or 24.41% of FY26 turnover) into Saarathi Healthcare Private Limited. Under the swap ratio, QMS shareholders will receive 1 equity share of Rs 10 each in Saarathi for every 1 share held in QMS. In parallel, QMS entered into an MOU to acquire 100% of BeamOptics Scientific Private Limited, which had FY26 turnover of Rs 113.81 Lakhs, with an expected completion timeline by November 30, 2027.
Confidence: HIGH
What changedQMS approved demerging its service arm into Saarathi Healthcare alongside a division of Health Care at Home India, while also agreeing to acquire BeamOptics Scientific.
Why it mattersThe demerger unlocks value by creating a dedicated listed healthcare services platform with separate management, while consolidating higher-margin PSP and healthcare service businesses.
Demerged division turnover (FY26): Rs. 37.17 CroresDemerged share of FY26 revenue: 24.41%Share exchange ratio (QMS to Saarathi): 1:1BeamOptics FY26 turnover: Rs. 113.81 LakhsDemerged business vs TTM revenue: ~20.3%
📅 Short termMarket is likely to view the corporate restructuring and separate listing of the high-margin service vertical positively, pending detailed scheme disclosures.
📈 Long termAllows QMS to sharpen its core operations while enabling Saarathi to operate as a focused healthcare services entity with distinct capital allocation and growth avenues.
⚠ Risk flags
- Execution timeline risk extending up to November 30, 2027 for acquisition completion
- Scheme is subject to approvals from NSE, SEBI, shareholders, creditors, and NCLT
Key Highlights
Demerged Healthcare Services business contributed Rs 37.17 Cr (24.41% of FY26 total turnover)
Share swap ratio of 1:1 for QMS shareholders into the resulting company (Saarathi Healthcare)
Post-arrangement Saarathi shareholding to consist of 40.5% promoters and 59.5% public (total 3,25,00,066 shares)
Agreed to acquire 100% of BeamOptics Scientific (FY26 turnover of Rs 113.81 Lakhs) on or before November 30, 2027
👀 What to Watch
Track the upcoming regulatory filings, shareholder and creditor approvals, and NCLT sanction timelines for the composite scheme of arrangement and the listing of Saarathi Healthcare.
Lemon Tree Hotels Opens 71-Key Lemon Tree Resort in Nashik, Maharashtra
Lemon Tree Hotels has announced the operational opening of Lemon Tree Resort, Nashik, featuring 71 rooms and suites. The property is managed by Carnation Hotels Private Limited, a wholly owned subsidiary of the company. This marks the group's second operational hotel in Nashik and its 16th operational hotel in Maharashtra, where it has another 16 properties in the pipeline. Relative to the company's operational portfolio of 10,956 rooms across 121 hotels, the 71-room addition represents an incremental capacity increase of approximately 0.65%.
Confidence: HIGH
What changedLemon Tree Hotels operationalized the Lemon Tree Resort, Nashik with 71 keys, an increase from the previously disclosed 57 keys.
Why it mattersAdds incremental asset-light management fee revenue under Carnation Hotels and strengthens Lemon Tree's footprint in Maharashtra's leisure and pilgrimage tourism market.
Rooms added: 71Originally disclosed room count: 57Operational hotels in Maharashtra: 16Pipeline hotels in Maharashtra: 16Added rooms vs total operational room inventory (~10,956): ~0.65%
📅 Short termMinimal near-term stock price impact given the small scale (71 keys), but reflects steady pipeline conversion into operational status.
📈 Long termSupports the company's asset-light expansion model via management contracts, contributing steady fee income without capex drag on the balance sheet.
⚠ Risk flags
- Execution of leisure demand ramp-up in a competitive regional hospitality market
Key Highlights
Opened Lemon Tree Resort, Nashik with 71 rooms and suites (up from 57 rooms initially planned)
Marks the Group's 2nd hotel in Nashik and 16th operational hotel in Maharashtra
Expansion pipeline includes 16 additional properties planned in Maharashtra
Property is managed by wholly owned subsidiary Carnation Hotels Private Limited
👀 What to Watch
Monitor quarterly RevPAR and occupancy trends for newly opened leisure properties, as well as management fee income contributions from subsidiary Carnation Hotels.
